Barbara Seliger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5050117/publications.pdf

Version: 2024-02-01

261	13,650	19657 61	29157 104
papers	citations	h-index	g-index

286	286	286	19680
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. Frontiers in Immunology, 2022, 13, 811200.	4.8	7
2	Abstract P1-08-34: Peripheral immunity predicts therapeutic outcomes in breast cancer patients. Cancer Research, 2022, 82, P1-08-34-P1-08-34.	0.9	0
3	Enhanced function of vaccine dendritic cells from obese donors upon inhibition of the lipid metabolism. Clinical and Translational Medicine, 2022, 12, e557.	4.0	0
4	Role of HLA-G in Viral Infections. Frontiers in Immunology, 2022, 13, 826074.	4.8	11
5	Novel approach to identify putative Epsteinâ€“Barrâ€“virus microRNAs regulating host cell genes with relevance in tumor biology and immunology. OncoImmunology, 2022, 11, 2070338.	4.6	1
6	Mortality factors in pancreatic surgery: A systematic review. How important is the hospital volume?. International Journal of Surgery, 2022, 101, 106640.	2.7	2
7	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. Cancer Research Communications, 2022, 2, 286-292.	1.7	2
8	Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells. OncoImmunology, 2022, 11, 2069214.	4.6	4
9	Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways. Frontiers in Immunology, 2022, 13, .	4.8	3
10	Identification and characterization of novel CD274 (PDâ€L1) regulating microRNAs and their functional relevance in melanoma. Clinical and Translational Medicine, 2022, 12, .	4.0	4
11	Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus â€negative oral squamous cell carcinomas with negative resection margins. Head and Neck, 2021, 43, 568-576.	2.0	3
12	Fluorescent spherical mesoporous silica nanoparticles loaded with emodin: Synthesis, cellular uptake and anticancer activity. Materials Science and Engineering C, 2021, 119, 111619.	7.3	15
13	Standardizing gene product nomenclatureâ€”a call to action. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	34
14	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. OncoImmunology, 2021, 10, 1860586.	4.6	40
15	Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia. Cancers, 2021, 13, 186.	3.7	8
16	Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma. Cancers, 2021, 13, 620.	3.7	11
17	What is the prospect of indoleamine 2,3-dioxygenase 1Âinhibition in cancer? Extrapolation from the past. Journal of Experimental and Clinical Cancer Research, 2021, 40, 60.	8.6	22
18	Immune Therapy Resistance and Immune Escape of Tumors. Cancers, 2021, 13, 551.	3.7	32

#	Article	IF	Citations
19	Identification of a novel miRâ€21â€3p/TGFâ€Î²2 signalingâ€driven immune escape via the MHC class I/biglycan axis in tumor cells. Clinical and Translational Medicine, 2021, 11, e306.	4.0	6
20	Relevance of 2â€²-O-Methylation and Pseudouridylation for the Malignant Melanoma. Cancers, 2021, 13, 1167.	3.7	5
21	Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues. Frontiers in Immunology, 2021, 12, 597399.	4.8	4
22	Endogenous Retroviralâ€“K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 657187.	2.8	16
23	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 2021, 13, 2594.	3.7	2
24	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. , 2021, 9, e002844.		29
25	Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma. Cancers, 2021, 13, 3907.	3.7	6
26	Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition. Cell Death Discovery, 2021, 7, 264.	4.7	7
27	A Chimeric IL-15/IL-15RÎ± Molecule Expressed on NFÎºB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells. International Journal of Molecular Sciences, 2021, 22, 10227.	4.1	5
28	Expression and Clinical Significance of SARS-CoV-2 Human Targets in Neoplastic and Non-Neoplastic Lung Tissues. Current Cancer Drug Targets, 2021, 21, 428-442.	1.6	8
29	Epsteinâ€“Barr Virusâ€”Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. Cancers, 2021, 13, 5189.	3.7	29
30	The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition. Frontiers in Immunology, 2021, 12, 714799.	4.8	4
31	An altered miTRAP method for miRNA affinity purification with its pros and cons. Methods in Enzymology, 2020, 636, 323-337.	1.0	3
32	Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche. Methods in Enzymology, 2020, 635, 67-79.	1.0	8
33	Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade. Journal of Immunotherapy, 2020, 43, 57-66.	2.4	36
34	Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma. Journal of Translational Medicine, 2020, 18, 371.	4.4	7
35	High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. Cancers, 2020, 12, 2966.	3.7	16
36	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 7032.	4.1	20

#	Article	IF	Citations
37	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. International Journal of Molecular Sciences, 2020, 21, 7140.	4.1	14
38	Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. , 2020, 8, e001261.		18
39	The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis. International Journal of Molecular Sciences, 2020, 21, 5209.	4.1	15
40	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	12.8	71
41	Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. Journal of Clinical Medicine, 2020, 9, 2690.	2.4	18
42	Current Understanding of the HIF-1-Dependent Metabolism in Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 6083.	4.1	20
43	Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. Journal of Translational Medicine, 2020, 18, 192.	4.4	7
44	DRH1 â€“ a novel blood-based HPV tumour marker. EBioMedicine, 2020, 56, 102804.	6.1	12
45	Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. , 2020, 8, e000266.		69
46	Sialylation of Human Natural Killer (NK) Cells Is Regulated by IL-2. Journal of Clinical Medicine, 2020, 9, 1816.	2.4	9
47	Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744. , 2020, 8, e000396.		18
48	Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. OncoImmunology, 2020, 9, 1774323.	4.6	27
49	Molecular mechanisms of human herpes viruses inferring with host immune surveillance. , 2020, 8, e000841.		17
50	â€œUniCARâ€•modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Scientific Reports, 2020, 10, 2141.	3.3	62
51	â€œTumor immunology meets oncology (TIMO) XVâ€‚April 25thâ€“27th 2019, Halle/Saale, Germany. Cancer Immunology, Immunotherapy, 2020, 69, 901-909.	4.2	0
52	What turns CREB on? And off? And why does it matter?. Cellular and Molecular Life Sciences, 2020, 77, 4049-4067.	5.4	92
53	Identification of immunomodulatory RNA-binding proteins in tumors. Methods in Enzymology, 2020, 636, 339-350.	1.0	0
54	CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. Scientific Reports, 2020, 10, 6499.	3.3	21

#	Article	IF	Citations
55	HLA Class I Antigen Processing Machinery Defects in Cancer Cellsâ€"Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. Methods in Molecular Biology, 2020, 2055, 325-350.	0.9	26
56	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatmentâ€"Review. Frontiers in Immunology, 2019, 10, 2043.	4.8	7
57	Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy, 2019, 68, 1689-1700.	4.2	68
58	PIR-B expressing CD8+ T cells exhibit features of Tc1 and Tc17 in SKG mice. Rheumatology, 2019, 58, 2325-2329.	1.9	2
59	Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism. International Journal of Molecular Sciences, 2019, 20, 4742.	4.1	19
60	Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. Methods in Molecular Biology, 2019, 1913, 13-31.	0.9	12
61	Identification of Immune Modulatory miRNAs by miRNA Enrichment via RNA Affinity Purification. Methods in Molecular Biology, 2019, 1913, 81-101.	0.9	5
62	TGF-Î² inducible epithelial-to-mesenchymal transition in renal cell carcinoma. Oncotarget, 2019, 10, 1507-1524.	1.8	19
63	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology, 2019, 10, 999.	4.8	47
64	â€œTumor Immunology Meets Oncology (TIMO) XIVâ€; May 24â€“26th 2018, Halle/Saale, Germany. Cancer Immunology, Immunotherapy, 2019, 68, 1725-1732.	4.2	0
65	Monoallelic expression in melanoma. Journal of Translational Medicine, 2019, 17, 112.	4.4	2
66	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. Frontiers in Immunology, 2019, 10, 2766.	4.8	23
67	NF-ÎºB activation triggers NK-cell stimulation by monocyte-derived dendritic cells. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989162.	3.2	20
68	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Research, 2019, 21, 142.	5.0	21
69	Basis of PD1/PD-L1 Therapies. Journal of Clinical Medicine, 2019, 8, 2168.	2.4	85
70	The tumor microenvironment: Thousand obstacles for effector T cells. Cellular Immunology, 2019, 343, 103730.	3.0	9
71	Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. Oncotarget, 2019, 10, 6509-6525.	1.8	4
72	Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patientsâ€™ Outcome. Current Cancer Drug Targets, 2019, 19, 210-221.	1.6	20

#	Article	IF	Citations
73	Immunotherapy of Breast Cancer. Breast Care, 2018, 13, 5-6.	1.4	5
74	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. Breast Care, 2018, 13, 16-21.	1.4	135
75	Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue. Cellular and Molecular Life Sciences, 2018, 75, 2241-2256.	5.4	24
76	NKp46 Receptor-Mediated Interferon-Î³ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity, 2018, 48, 107-119.e4.	14.3	143
77	T-cell Responses in the Microenvironment of Primary Renal Cell Carcinomaâ€"Implications for Adoptive Cell Therapy. Cancer Immunology Research, 2018, 6, 222-235.	3.4	59
78	Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. OncoImmunology, 2018, 7, e1373233.	4.6	19
79	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. OncoImmunology, 2018, 7, e1526613.	4.6	60
80	Receptor activator of NF-ÎºB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 502.e15-502.e24.	1.6	6
81	Kallikreinâ€related peptidases are activators of the CC chemokine CCL14. European Journal of Immunology, 2018, 48, 1592-1594.	2.9	4
82	Loss of epithelium-specific GPx2 results in aberrant cell fate decisions during intestinal differentiation. Oncotarget, 2018, 9, 539-552.	1.8	17
83	Methionine and seleno-methionine type peptide and peptoid building blocks synthesized by five-component five-center reactions. Chemical Communications, 2017, 53, 3777-3780.	4.1	7
84	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology, 2017, 6, e1253654.	4.6	146
85	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. OncoImmunology, 2017, 6, e1171447.	4.6	64
86	Altered protein expression pattern in colon tissue of mice upon supplementation with distinct selenium compounds. Proteomics, 2017, 17, 1600486.	2.2	6
87	Immunotherapy for metastatic renal cell carcinoma. The Cochrane Library, 2017, 2017, CD011673.	2.8	31
88	High constitutive B7-H3 expression on human keratinocytes supports T cell immunity. Journal of Dermatological Science, 2017, 87, 82-85.	1.9	1
89	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer, 2017, 81, 116-129.	2.8	443
90	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20

#	Article	IF	Citations
91	Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape. Journal of the National Cancer Institute, 2017, 109, .	6.3	121
92	Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid. OncoImmunology, 2017, 6, e1259049.	4.6	20
93	The role of the miRâ€148/â€152 family in physiology and disease. European Journal of Immunology, 2017, 47, 2026-2038.	2.9	87
94	Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors. Cytokine and Growth Factor Reviews, 2017, 36, 49-56.	7.2	17
95	AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nature Cell Biology, 2017, 19, 844-855.	10.3	132
96	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
97	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
98	Individual effects of different selenocompounds on the hepatic proteome and energy metabolism of mice. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 3323-3334.	2.4	25
99	Multiparametric immune profiling in HPVâ€“ oral squamous cell cancer. JCI Insight, 2017, 2, .	5.0	149
100	Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients. Oncotarget, 2017, 8, 21212-21228.	1.8	10
101	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget, 2017, 8, 48507-48520.	1.8	63
102	Adiponectin and Its Receptors Are Differentially Expressed in Human Tissues and Cell Lines of Distinct Origin. Obesity Facts, 2017, 10, 569-583.	3.4	27
103	Linking CREB function with altered metabolism in murine fibroblast-based model cell lines. Oncotarget, 2017, 8, 97439-97463.	1.8	18
104	Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target. Oncotarget, 2016, 7, 35454-35465.	1.8	104
105	Disentangling the relationship between tumor genetic programs and immune responsiveness. Current Opinion in Immunology, 2016, 39, 150-158.	5.5	57
106	HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins. Journal of Immunology, 2016, 196, 4967-4976.	0.8	46
107	Redox proteomics: Methods for the identification and enrichment of redoxâ€modified proteins and their applications. Proteomics, 2016, 16, 197-213.	2.2	67
108	Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology, 2016, 12, 879-893.	3.0	8

#	Article	IF	Citations
109	Cellular Aging and Tumor Regulation. Healthy Ageing and Longevity, 2016, , 187-201.	0.2	0
110	Molecular mechanisms of <scp>HLA</scp> class Iâ€mediated immune evasion of human tumors and their role in resistance to immunotherapies. Hla, 2016, 88, 213-220.	0.6	43
111	LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metabolism, 2016, 24, 657-671.	16.2	1,126
112	Role of microRNAs on HLA-G expression in human tumors. Human Immunology, 2016, 77, 760-763.	2.4	22
113	Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care, 2016, 11, 108-115.	1.4	45
114	Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. Journal of Translational Medicine, 2016, 14, 85.	4.4	79
115	Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIRâ€1+CD8+ T Cells. Arthritis and Rheumatology, 2016, 68, 337-346.	5.6	21
116	Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. OncoImmunology, 2016, 5, e1052213.	4.6	51
117	Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. Oncotarget, 2016, 7, 52061-52084.	1.8	11
118	HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget, 2016, 7, 67360-67372.	1.8	38
119	Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Oncotarget, 2016, 7, 20410-20424.	1.8	7
120	Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Oncotarget, 2016, 7, 26866-26878.	1.8	40
121	Different maturation cocktails provide dendritic cells with different chemoattractive properties. Journal of Translational Medicine, 2015, 13, 175.	4.4	29
122	Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0139809.	2.5	26
123	Tregs activated by bispecific antibodies. OncoImmunology, 2015, 4, e994441.	4.6	9
124	Hydrogen peroxide â€“ production, fate and role in redox signaling of tumor cells. Cell Communication and Signaling, 2015, 13, 39.	6.5	390
125	â€œTumor immunology meets oncologyâ€•(TIMO) X, May 23â€“24, 2014, Halle/Saale, Germany. Cancer Immunology, Immunotherapy, 2015, 64, 519-526.	4.2	2
126	Role of signal transduction and microRNAs on the immunogenicity of melanoma cells. Journal of Translational Medicine, 2015, 13, .	4.4	1

#	Article	IF	Citations
127	Immune signature of tumor infiltrating immune cells in renal cancer. OncoImmunology, 2015, 4, e985082.	4.6	162
128	Colorectal Carcinogenesis: Connecting K-RASâ€“Induced Transformation and CREB Activity In Vitro and In Vivo. Molecular Cancer Research, 2015, 13, 1248-1262.	3.4	22
129	Molecular mechanism of CHRDL1-mediated X-linked megalocornea in humans and in Xenopus model. Human Molecular Genetics, 2015, 24, 3119-3132.	2.9	24
130	Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. OncoImmunology, 2015, 4, e1008342.	4.6	19
131	Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. OncoImmunology, 2015, 4, e1008805.	4.6	58
132	Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogens. European Journal of Medicinal Chemistry, 2015, 90, 267-279.	5.5	15
133	Impact of the mitogenâ€activated protein kinase pathway on the subproteome of detergentâ€resistant microdomains of colon carcinoma cells. Proteomics, 2015, 15, 77-88.	2.2	2
134	Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. Oncotarget, 2015, 6, 11395-11406.	1.8	23
135	VHL-dependent alterations in the secretome of renal cell carcinoma: Association with immune cell response?. Oncotarget, 2015, 6, 43420-43437.	1.8	8
136	Role of the Non-classical HLA Class I Antigens for Immune Escape. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 59-72.	0.1	0
137	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
138	Identification of 14-3-3Î² Gene as a Novel miR-152 Target Using a Proteome-based Approach. Journal of Biological Chemistry, 2014, 289, 31121-31135.	3.4	22
139	The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors. Journal of Immunotoxicology, 2014, 11, 308-310.	1.7	33
140	Towards defining biomarkers indicating resistances to targeted therapies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 909-916.	2.3	9
141	Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactions. Atherosclerosis, 2014, 237, 443-452.	0.8	17
142	A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA. Modern Pathology, 2014, 27, 1296-1305.	5.5	5
143	Synergistic effects of IL-4 and TNFÎ± on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. Journal of Translational Medicine, 2014, 12, 151.	4.4	52
144	Granulocyteâ€toâ€dendritic cellâ€ratio as marker for the immune monitoring in patients with renal cell carcinoma. Clinical and Translational Medicine, 2014, 3, 13.	4.0	5

#	Article	IF	Citations
145	The Role of MicroRNAs in the Control of Innate Immune Response in Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	57
146	Multiple readout assay for hormonal (androgenic and antiandrogenic) and cytotoxic activity of plant and fungal extracts based on differential prostate cancer cell line behavior. Journal of Ethnopharmacology, 2014, 155, 721-730.	4.1	20
147	Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity. Clinical Cancer Research, 2014, 20, 4096-4106.	7.0	230
148	B7-H Abnormalities in Melanoma and Clinical Relevance. Methods in Molecular Biology, 2014, 1102, 367-380.	0.9	3
149	Discrimination between Von Hippel-Lindau gene and hypoxia-regulated alterations in the metabolism and protein expression in renal cell carcinoma using ome-based strategies.. Journal of Clinical Oncology, 2014, 32, 447-447.	1.6	0
150	Predictive immunomonitoring â€" The COST ENTIRE initiative. Clinical Immunology, 2013, 147, 23-26.	3.2	13
151	HLA-dependent tumour development: a role for tumour associate macrophages?. Journal of Translational Medicine, 2013, 11, 247.	4.4	55
152	Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. International Journal of Cancer, 2013, 133, n/a-n/a.	5.1	19
153	The two sides of HER2/neu: immune escape versus surveillance. Trends in Molecular Medicine, 2013, 19, 677-684.	6.7	17
154	Fast Dendritic Cells Stimulated with Alternative Maturation Mixtures Induce Polyfunctional and Long-Lasting Activation of Innate and Adaptive Effector Cells with Tumor-Killing Capabilities. Journal of Immunology, 2013, 190, 3328-3337.	0.8	20
155	The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer. Journal of Immunology, 2013, 191, 6261-6272.	0.8	79
156	The prognostic impact of human leukocyte antigen (<scp>HLA</scp>) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. Histopathology, 2013, 62, 847-859.	2.9	8
157	HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function. Molecular Cancer Research, 2013, 11, 1462-1477.	3.4	30
158	Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors. Journal of Biological Chemistry, 2013, 288, 16334-16347.	3.4	53
159	The Dark Side of Dendritic Cells: Development and Exploitation of Tolerogenic Activity That Favor Tumor Outgrowth and Immune Escape. Frontiers in Immunology, 2013, 4, 419.	4.8	15
160	Expression and function of CTLA4 in melanoma.. Journal of Clinical Oncology, 2013, 31, e20040-e20040.	1.6	4
161	Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes. International Journal of Clinical and Experimental Pathology, 2013, 6, 998-1008.	0.5	7
162	The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors. Clinical Transplants, 2013, , 465-72.	0.2	4

#	Article	IF	Citations
163	Opposing consequences of signaling through EGF family members. OncoImmunology, 2012, 1, 1200-1201.	4.6	2
164	HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties. Journal of Biological Chemistry, 2012, 287, 24320-24329.	3.4	28
165	Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis, 2012, 33, 781-790.	2.8	13
166	Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation, 2012, 93, 744-749.	1.0	47
167	Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunology, Immunotherapy, 2012, 61, 1243-1253.	4.2	34
168	The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunology, Immunotherapy, 2012, 61, 1327-1341.	4.2	72
169	The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine, 2012, 18, 128-134.	6.7	308
170	Predominance of Th2 cells and plasma cells in polyoma virus nephropathy: a role for humoral immunity?. Human Pathology, 2012, 43, 1453-1462.	2.0	12
171	A Proteomic View at T Cell Costimulation. PLoS ONE, 2012, 7, e32994.	2.5	18
172	HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines. Journal of Immunology, 2012, 188, 2136-2145.	0.8	51
173	The role of classical and non-classical HLA class I antigens in human tumors. Seminars in Cancer Biology, 2012, 22, 350-358.	9.6	137
174	Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunology, Immunotherapy, 2012, 61, 249-254.	4.2	67
175	Comparative Expression Profiling of Distinct T Cell Subsets Undergoing Oxidative Stress. PLoS ONE, 2012, 7, e41345.	2.5	15
176	Linkage of microRNA and Proteome-Based Profiling Data Sets: A Perspective for the Priorization of Candidate Biomarkers in Renal Cell Carcinoma?. Journal of Proteome Research, 2011, 10, 191-199.	3.7	11
177	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
178	Monitoring peri-operative immune suppression in renal cancer patients. Oncology Reports, 2011, 25, 1455-64.	2.6	12
179	Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clinical Immunology, 2011, 140, 71-83.	3.2	69
180	Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns. Molecular Genetics and Genomics, 2011, 286, 279-91.	2.1	6

#	Article	IF	Citations
181	Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?. Cellular and Molecular Life Sciences, 2011, 68, 417-431.	5.4	116
182	Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells. Proteomics, 2011, 11, 2528-2541.	2.2	17
183	Warburg phenotype in renal cell carcinoma: High expression of glucoseâ€transporter 1 (GLUTâ€1) correlates with low CD8⁺ Tâ€cell infiltration in the tumor. International Journal of Cancer, 2011, 128, 2085-2095.	5.1	122
184	T cell recognition of HLAâ€A2 restricted tumor antigens is impaired by the oncogene HER2. International Journal of Cancer, 2011, 128, 390-401.	5.1	53
185	Association of IFN-Î³ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines. Clinical Cancer Research, 2011, 17, 2668-2678.	7.0	67
186	B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response. Clinical Cancer Research, 2011, 17, 3100-3111.	7.0	122
187	Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunology, Immunotherapy, 2010, 59, 529-540.	4.2	77
188	Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunology, Immunotherapy, 2010, 59, 1273-1284.	4.2	41
189	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HERâ€2/neu oncogeneâ€driven animal model system. Proteomics, 2010, 10, 3835-3853.	2.2	10
190	Survival of the fittest or best adapted: HLA-dependent tumor development. Journal of Nucleic Acids Investigation, 2010, 1, 9.	0.8	3
191	Identification of E2F1 as an Important Transcription Factor for the Regulation of Tapasin Expression. Journal of Biological Chemistry, 2010, 285, 30419-30426.	3.4	34
192	Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends in Molecular Medicine, 2010, 16, 184-192.	6.7	26
193	Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma. Molecular and Cellular Proteomics, 2009, 8, 2827-2842.	3.8	27
194	CIITA versus IFN-Î³ induced MHC class II expression in head and neck cancer cells. Archives of Dermatological Research, 2009, 301, 189-193.	1.9	20
195	HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunology, Immunotherapy, 2009, 58, 653-664.	4.2	48
196	The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunology, Immunotherapy, 2009, 58, 1599-1608.	4.2	14
197	Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics, 2009, 9, 1567-1581.	2.2	38
198	Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. Journal of Translational Medicine, 2009, 7, 90.	4.4	26

#	Article	IF	Citations
199	Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunology, Immunotherapy, 2008, 57, 1719-1726.	4.2	131
200	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 2008, 6, 81.	4.4	45
201	The complex role of B7 molecules in tumor immunology. Trends in Molecular Medicine, 2008, 14, 550-559.	6.7	84
202	Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion. Molecular Membrane Biology, 2008, 25, 72-82.	2.0	29
203	Different regulation of MHC Class I antigen processing components in human tumors. Journal of Immunotoxicology, 2008, 5, 361-367.	1.7	53
204	Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17481-17486.	7.1	177
205	Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors. Advances in Cancer Research, 2008, 101, 249-276.	5.0	84
206	Altered Detoxification Status and Increased Resistance to Oxidative Stress by K-Ras Transformation. Cancer Research, 2008, 68, 10086-10093.	0.9	45
207	High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?. Nephrology Dialysis Transplantation, 2007, 22, 2795-2799.	0.7	36
208	Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1]. Clinical Cancer Research, 2007, 13, 27-37.	7.0	55
209	Influence ofKi-ras-driven oncogenic transformation on the protein network of murine fibroblasts. Proteomics, 2007, 7, 385-398.	2.2	20
210	Candidate biomarkers in renal cell carcinoma. Proteomics, 2007, 7, 4601-4612.	2.2	36
211	Structure, expression and function of HLA-G in renal cell carcinoma. Seminars in Cancer Biology, 2007, 17, 444-450.	9.6	30
212	HLA Class I Antigen Abnormalities in Tumors. , 2007, , 123-144.		0
213	Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. International Journal of Cancer, 2006, 118, 129-138.	5.1	110
214	Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Research, 2006, 66, 6387-6394.	0.9	58
215	Common Cancer Biomarkers. Cancer Research, 2006, 66, 2953-2961.	0.9	96
216	Identification and validation of novelERBB2(HER2,NEU) targets including genes involved in angiogenesis. International Journal of Cancer, 2005, 114, 590-597.	5.1	53

#	Article	IF	Citations
217	Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics, 2005, 5, 2631-2640.	2.2	36
218	Heat Shock Proteins in Renal Cell Carcinomas. , 2005, 148, 35-56.		23
219	B7/CD28 Costimulation of T Cells Induces a Distinct Proteome Pattern. Molecular and Cellular Proteomics, 2005, 4, 1876-1887.	3.8	8
220	Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome. Clinical Cancer Research, 2005, 11, 2552-2560.	7.0	222
221	Restoration of the Expression of Transporters Associated with Antigen Processing in Lung Carcinoma Increases Tumor-Specific Immune Responses and Survival. Cancer Research, 2005, 65, 7926-7933.	0.9	84
222	Strategies of Tumor Immune Evasion. BioDrugs, 2005, 19, 347-354.	4.6	120
223	HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway. Cancer Research, 2004, 64, 215-220.	0.9	110
224	Ontogeny and Oncogenesis Balance the Transcriptional Profile of Renal Cell Cancer. Cancer Research, 2004, 64, 7279-7287.	0.9	33
225	Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. International Journal of Cancer, 2004, 108, 71-77.	5.1	138
226	CD4+T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. International Journal of Cancer, 2004, 109, 259-264.	5.1	46
227	MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. International Journal of Cancer, 2004, 109, 265-273.	5.1	111
228	Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas. International Journal of Cancer, 2004, 109, 636-638.	5.1	27
229	Down-Regulation of HLA Class I Antigen Processing Molecules: An Immune Escape Mechanism of Renal Cell Carcinoma?. Journal of Urology, 2004, 171, 885-889.	0.4	94
230	Melanoma-restricted genes. Journal of Translational Medicine, 2004, 2, 34.	4.4	50
231	The role of HLA-G for protection of human renal cellâ€“carcinoma cells from immune-mediated lysis: implications for immunotherapies. Seminars in Cancer Biology, 2003, 13, 353-359.	9.6	20
232	Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1646, 21-31.	2.3	75
233	Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics, 2003, 3, 979-990.	2.2	43
234	Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Human Immunology, 2003, 64, 1081-1092.	2.4	32

#	Article	IF	Citations
235	Cloning and functional analyses of the mouse tapasin promoter. Immunogenetics, 2003, 55, 379-388.	2.4	17
236	HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends in Immunology, 2003, 24, 82-87.	6.8	96
237	Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses. Briefings in Functional Genomics & Proteomics, 2003, 2, 194-212.	3.8	22
238	Impaired Transporter Associated with Antigen Processing (TAP) Function Attributable to a Single Amino Acid Alteration in the Peptide TAP Subunit TAP1. Journal of Immunology, 2003, 170, 941-946.	0.8	19
239	Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clinical Cancer Research, 2003, 9, 1721-7.	7.0	87
240	A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Research, 2003, 63, 4095-100.	0.9	171
241	Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Research, 2003, 63, 4107-11.	0.9	108
242	Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. International Journal of Oncology, 2003, 23, 991-9.	3.3	5
243	Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Research, 2003, 63, 7221-31.	0.9	34
244	Tuning tumor-specific T-cell activation: a matter of costimulation?. Trends in Immunology, 2002, 23, 240-245.	6.8	76
245	Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics, 2002, 2, 561-570.	2.2	66
246	Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics, 2002, 2, 1641-1651.	2.2	82
247	Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics, 2002, 2, 1743-1751.	2.2	81
248	HLA class I antigen abnormalities and immune escape by malignant cells. Seminars in Cancer Biology, 2002, 12, 3-13.	9.6	233
249	High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. International Journal of Oncology, 2002, 20, 349-53.	3.3	4
250	Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Research, 2002, 62, 2856-60.	0.9	23
251	Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Electrophoresis, 2001, 22, 1801-1809.	2.4	27
252	Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. International Immunology, 2001, 13, 1515-1523.	4.0	48

#	Article	IF	Citations
253	HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. International Journal of Cancer, 2000, 87, 349-359.	5.1	57
254	Antigen-processing machinery breakdown and tumor growth. Trends in Immunology, 2000, 21, 455-464.	7.5	395
255	Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer. , 1999, 81, 125-133.		32
256	Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. , 1999, 81, 979-984.		13
257	Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. European Journal of Immunology, 1998, 28, 122-133.	2.9	86
258	Strong Immunogenic Potential of a B7 Retroviral Expression Vector: Generation of HLA-B7-Restricted CTL Response Against Selectable Marker Genes. Human Gene Therapy, 1998, 9, 53-62.	2.7	31
259	Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. European Journal of Immunology, 1994, 24, 759-764.	2.9	383
260	Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. British Journal of Haematology, 1994, 88, 794-802.	2.5	68
261	The Role of Immune Modulatory MicroRNAs in Tumors. , 0, , .		1